AstraZeneca: New HQ And R&D Site Underscore Its U.K. Commitment
This article was originally published in The Pink Sheet Daily
Executive Summary
Design plans for AstraZeneca’s new, purpose-built global headquarters and R&D center being constructed in the university town Cambridge underscore the pure pharma’s commitment to innovative science as a standalone, U.K.-based company, says head of early development Menelas Panaglos.
You may also be interested in...
AstraZeneca’s Menelas Pangalos: An Interview With “The Pink Sheet” DAILY
With AstraZeneca in the midst of a major R&D overhaul, Menelas Pangalos, the company’s head of discovery research and early-stage development in small molecules, talked to “The Pink Sheet” DAILY about how the new R&D structure will improve the big pharma’s research productivity.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.
Incyte Plays Down Ruxolitinib Cream Label Worries Following Atopic Dermatitis Approval
Incyte welcomed FDA approval of its ruxolitinib cream, a selective JAK1/JAK2 inhibitor, as a treatment for atopic dermatitis, but criticized the boxed warnings label assigned to it.